Literature DB >> 9160259

Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry.

N V Phadnis1, R K Cavatur, R Suryanarayanan.   

Abstract

A simple X-ray powder diffractometric (XRD) method was developed for the identification of the active ingredient in a variety of dosage forms. The method was successfully used to unambiguously identify the active ingredient(s) in tablet, capsule, suppository and ointment formulations. The unique feature of the method is that it provides information about the solid-state of the drug. Thus, a capsule formulation containing anhydrous ampicillin was readily distinguished from that containing ampicillin trihydrate. The USP stipulates the use of the beta-polymorphic form of anhydrous carbamazepine in carbamazepine tablets. Contamination by the alpha-polymorph (down to a level of 1.4% w/w of the formulation) could be detected. In some of the multicomponent formulations, there was a pronounced overlap of the powder patterns of ingredients which made identification difficult. This problem was solved by using a pattern subtraction technique, which permitted selective subtraction of the XRD pattern of the constituents of the formulation from the overall XRD pattern. Such an approach enabled identification of the drug even when it constituted only 5% w/w of the formulation. The method also permitted simultaneous identification of the multiple active ingredients in trimethoprim-sulfamethoxazole and acetaminophen-aspirin-caffeine formulations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160259     DOI: 10.1016/s0731-7085(96)01939-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry.

Authors:  G M Venkatesh; M E Barnett; C Owusu-Fordjour; M Galop
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

2.  A structural investigation into the compaction behavior of pharmaceutical composites using powder X-ray diffraction and total scattering analysis.

Authors:  Michael D Moore; Alison M Steinbach; Ira S Buckner; Peter L D Wildfong
Journal:  Pharm Res       Date:  2009-08-28       Impact factor: 4.200

3.  Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods.

Authors:  Ziyaur Rahman; Ahmed S Zidan; Mansoor A Khan
Journal:  AAPS J       Date:  2010-02-03       Impact factor: 4.009

Review 4.  Current and Future Perspective of Devices and Diagnostics for Opioid and OIRD.

Authors:  Naveen K Singh; Gurpreet K Sidhu; Kuldeep Gupta
Journal:  Biomedicines       Date:  2022-03-22

5.  Solid-state characterization of nevirapine.

Authors:  Mahua Sarkar; O P Perumal; R Panchagnula
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

6.  Solid-State Characterization and Compatibility Studies of Penciclovir, Lysine Hydrochloride, and Pharmaceutical Excipients.

Authors:  Rafaela Z C Meira; Isabela F B Biscaia; Camila Nogueira; Fabio S Murakami; Larissa S Bernardi; Paulo R Oliveira
Journal:  Materials (Basel)       Date:  2019-09-27       Impact factor: 3.623

7.  X-ray fan beam coded aperture transmission and diffraction imaging for fast material analysis.

Authors:  Stefan Stryker; Joel A Greenberg; Shannon J McCall; Anuj J Kapadia
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

8.  Insight into the Inclusion Complexation of Fluconazole with Sulfonatocalix[4]naphthalene in Aqueous Solution, Solid-State, and Its Antimycotic Activity.

Authors:  Tayel A Al Hujran; Mousa K Magharbeh; Almeqdad Y Habashneh; Rasha S Al-Dmour; Ashraf Aboelela; Hesham M Tawfeek
Journal:  Molecules       Date:  2022-07-11       Impact factor: 4.927

Review 9.  An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services.

Authors:  Lane Harper; Jeff Powell; Em M Pijl
Journal:  Harm Reduct J       Date:  2017-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.